Table 3 Multivariate analysis for GVHD
|  | Acute GVHD II–IV | Acute GVHD III–IV | Chronic GVHD | Ext. chronic GVHD | ||||
|---|---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
ATG vs PTCY | 0.98 (0.66–1.46) | 0.93 | 0.84 (0.42–1.71) | 0.64 | 1.22 (0.79–1.87) | 0.37 | 0.64 (0.37–1.09) | 0.09 |
Age (per 10 years) | 1 (0.91–1.09) | 0.92 | 1.01 (0.86–1.18) | 0.92 | 1.06 (0.97–1.16) | 0.20 | 1.03 (0.89–1.18) | 0.73 |
sec. AML vs de novo | 1.23 (0.95–1.61) | 0.12 | 1.26 (0.79–2) | 0.34 | 1.01 (0.76–1.33) | 0.96 | 1.62 (1.1–2.39) | 0.01 |
Adverse cytogenetics vs other | 0.94 (0.74–1.21) | 0.65 | 1.12 (0.73–1.71) | 0.60 | 0.73 (0.56–0.96) | 0.03 | 0.61 (0.39–0.95) | 0.03 |
Female donor-male recipient vs other | 1.27 (0.96–1.68) | 0.10 | 1.67 (1.05–2.66) | 0.03 | 1.07 (0.79–1.45) | 0.65 | 1.05 (0.66–1.67) | 0.83 |
RIC vs MAC | 0.79 (0.62–1) | 0.046 | 0.89 (0.59–1.36) | 0.60 | 0.97 (0.76–1.23) | 0.79 | 0.78 (0.54–1.14) | 0.20 |
KPS ≥ 90 | 0.83 (0.65–1.06) | 0.13 | 0.64 (0.42–0.97) | 0.03 | 0.91 (0.71–1.17) | 0.45 | 0.92 (0.63–1.34) | 0.67 |
Patient CMV positivity | 1.05 (0.85–1.31) | 0.64 | 1.01 (0.68–1.48) | 0.98 | 1.28 (1.03–1.6) | 0.03 | 1.05 (0.75–1.47) | 0.77 |
Donor CMV positivity | 1 (0.81–1.23) | 0.99 | 1.06 (0.73–1.53) | 0.77 | 0.97 (0.79–1.2) | 0.80 | 1.32 (0.96–1.82) | 0.09 |
Year of transplantation | 1.01 (0.96–1.06) | 0.75 | 1.03 (0.94–1.12) | 0.57 | 1 (0.95–1.05) | 0.94 | 1.07 (0.99–1.16) | 0.09 |
PBSC vs BM | 1.05 (0.75–1.47) | 0.77 | 1.1 (0.6–2) | 0.76 | 1.1 (0.78–1.55) | 0.59 | 1.37 (0.79–2.4) | 0.26 |